CORT's Q3 Earnings Beat, Higher Product Sales Aid Y/Y Revenues

Corcept’s Q3 2026 earnings were $1.01 per share versus 68 cents expected, while revenue rose 64% year over year to $340.5 million versus $329 million expected. Lifyorli generated $91.4 million, up 92% sequentially and above the $70 million model estimate, offsetting a miss in Korlym and authorized-generic sales; Corcept reaffirmed 2026 revenue guidance of $1.1 billion–$1.2 billion. The company also reported positive phase II BELLA results and an EU committee recommendation for Lifyorli, while its relacorilant application remains under FDA review with a Dec. 17, 2026 target action date.

Analysis

The earnings quality is better than a Korlym-led beat, but not yet a durable launch curve: Lifyorli is the marginal growth engine while Korlym’s miss versus model leaves legacy-product pricing/volume as a watch item. The key diligence point is whether new-patient starts convert to persistent treatment and repeat revenue; physician counts and launch-period uptake alone do not establish that. SG&A growth also means commercial leverage is not yet proven, so incremental sales need to translate into operating margin rather than simply larger selling spend.

Near term, an in-line full-year outlook after a large YTD rerating may cap upside despite the headline beat. The next 1–3 month catalysts are the Dec. 17 FDA action on relacorilant for Cushing’s and the European Commission decision on Lifyorli. A positive ruling could broaden the addressable market, but the BELLA triplet data are phase II and should not be capitalized as established standard-of-care economics. Longer term, the Avastin combination may create incremental use of Roche’s product, but adoption depends on confirmatory evidence and clinical practice—not just response-rate headlines.

Contrarian read: investors may be extrapolating early Lifyorli uptake too aggressively, while underweighting the value of a second commercial franchise if persistence holds. Conversely, Korlym’s growth does not eliminate generic/pricing exposure. Without valuation, share price, and launch persistence data, the 135% YTD move argues against chasing rather than proving fundamental overvaluation. Falsifiers: sustained Lifyorli deceleration, a guidance reduction, weak commercial-margin conversion, or an FDA delay/negative action.

Key Decisions for Investors

• Do not add to CORT solely on the quarterly beat after the substantial YTD rerating. For existing exposure, consider trimming into strength or maintaining only a sized core through the Dec. 17 FDA decision; reassess against valuation and post-approval commercial data.
• Set an alert for the next report: track Lifyorli new starts versus refill/persistence, net sales, and SG&A as a share of revenue. Persistent growth with improving expense leverage supports re-entry; deceleration or rising selling intensity without revenue conversion invalidates the launch thesis.
• Treat Cushing’s FDA action and the European Commission decision as binary catalysts. If taking event exposure, prefer a defined-risk call spread over unhedged options only if premiums and liquidity are acceptable; avoid paying for BELLA phase II results as though triplet approval were assured.
• Monitor Korlym/authorized-generic revenue and any pricing or volume commentary separately from Lifyorli. A sequential decline alongside slowing Lifyorli would expose the business to a weaker underlying franchise mix and argue for reducing exposure.